MX2010003711A - Derivados de tetrahidroquinolina para tratar trastornos por estres post-traumatico. - Google Patents
Derivados de tetrahidroquinolina para tratar trastornos por estres post-traumatico.Info
- Publication number
- MX2010003711A MX2010003711A MX2010003711A MX2010003711A MX2010003711A MX 2010003711 A MX2010003711 A MX 2010003711A MX 2010003711 A MX2010003711 A MX 2010003711A MX 2010003711 A MX2010003711 A MX 2010003711A MX 2010003711 A MX2010003711 A MX 2010003711A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- traumatic stress
- stress disorders
- treating post
- tetrahydroquinoline derivatives
- Prior art date
Links
- 208000028173 post-traumatic stress disease Diseases 0.000 title abstract 2
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007054130 | 2007-10-10 | ||
| PCT/IB2008/054138 WO2009047723A2 (en) | 2007-10-10 | 2008-10-09 | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010003711A true MX2010003711A (es) | 2010-04-30 |
Family
ID=40467356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010003711A MX2010003711A (es) | 2007-10-10 | 2008-10-09 | Derivados de tetrahidroquinolina para tratar trastornos por estres post-traumatico. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9532985B2 (enExample) |
| EP (1) | EP2207550B1 (enExample) |
| JP (1) | JP5883222B2 (enExample) |
| KR (1) | KR101733247B1 (enExample) |
| CN (1) | CN101820878B (enExample) |
| AR (1) | AR068768A1 (enExample) |
| AU (1) | AU2008309194B2 (enExample) |
| BR (1) | BRPI0818617A2 (enExample) |
| CA (1) | CA2699504C (enExample) |
| CY (1) | CY1114799T1 (enExample) |
| DK (1) | DK2207550T3 (enExample) |
| EA (1) | EA017443B1 (enExample) |
| ES (1) | ES2444418T3 (enExample) |
| HR (1) | HRP20140214T1 (enExample) |
| IL (1) | IL204838A (enExample) |
| MA (1) | MA31800B1 (enExample) |
| MX (1) | MX2010003711A (enExample) |
| MY (1) | MY153044A (enExample) |
| NZ (1) | NZ585086A (enExample) |
| PE (1) | PE20091010A1 (enExample) |
| PL (1) | PL2207550T3 (enExample) |
| PT (1) | PT2207550E (enExample) |
| SI (1) | SI2207550T1 (enExample) |
| TW (1) | TWI428129B (enExample) |
| UA (1) | UA99150C2 (enExample) |
| WO (1) | WO2009047723A2 (enExample) |
| ZA (1) | ZA201003251B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2380391T3 (es) | 2006-12-22 | 2012-05-11 | Actelion Pharmaceuticals Ltd. | Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina |
| US20110105514A1 (en) | 2008-06-25 | 2011-05-05 | Hamed Aissaoui | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
| EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
| TW201209037A (en) | 2010-08-24 | 2012-03-01 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| SI2626350T1 (sl) | 2010-09-22 | 2015-09-30 | Eisai R&D Management Co., Ltd. | Spojina ciklopropana |
| WO2012063207A1 (en) | 2010-11-10 | 2012-05-18 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
| WO2012110986A1 (en) | 2011-02-18 | 2012-08-23 | Actelion Pharmaceuticals Ltd | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| DK2776430T3 (en) | 2011-11-08 | 2016-05-09 | Actelion Pharmaceuticals Ltd | 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists |
| TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
| AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| JP6496733B2 (ja) | 2013-12-03 | 2019-04-03 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | （ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用 |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| KR102330133B1 (ko) | 2013-12-04 | 2021-11-23 | 이도르시아 파마슈티컬스 리미티드 | 벤즈이미다졸-프롤린 유도체의 용도 |
| SG10202007759RA (en) | 2014-10-23 | 2020-09-29 | Eisai R&D Man Co Ltd | Compositions and methods for treating insomnia |
| CN115710250A (zh) * | 2017-08-01 | 2023-02-24 | 博健制药有限责任公司 | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020007977A1 (en) | 2018-07-06 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 7-trifluoromethyl-[1,4]diazepan derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| TW202400149A (zh) | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6011301A (en) * | 2000-03-14 | 2001-09-24 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisoquinoline derivatives |
| AU2004224156B2 (en) * | 2003-03-26 | 2010-08-12 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists |
| JP4094050B2 (ja) * | 2004-03-01 | 2008-06-04 | アクテリオン ファーマシューティカルズ リミテッド | 置換１，２，３，４−テトラヒドロイソキノリン誘導体 |
| US7501395B2 (en) * | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| EP1998774A1 (en) | 2006-03-15 | 2008-12-10 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinoline derivatives to enhance memory function |
| EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
-
2008
- 2008-10-07 PE PE2008001739A patent/PE20091010A1/es not_active Application Discontinuation
- 2008-10-09 DK DK08807937.1T patent/DK2207550T3/da active
- 2008-10-09 WO PCT/IB2008/054138 patent/WO2009047723A2/en not_active Ceased
- 2008-10-09 SI SI200831152T patent/SI2207550T1/sl unknown
- 2008-10-09 AU AU2008309194A patent/AU2008309194B2/en not_active Ceased
- 2008-10-09 KR KR1020107010186A patent/KR101733247B1/ko not_active Expired - Fee Related
- 2008-10-09 EP EP08807937.1A patent/EP2207550B1/en active Active
- 2008-10-09 US US12/681,802 patent/US9532985B2/en not_active Expired - Fee Related
- 2008-10-09 ES ES08807937.1T patent/ES2444418T3/es active Active
- 2008-10-09 CN CN2008801113334A patent/CN101820878B/zh not_active Expired - Fee Related
- 2008-10-09 JP JP2010528515A patent/JP5883222B2/ja not_active Expired - Fee Related
- 2008-10-09 EA EA201000557A patent/EA017443B1/ru not_active IP Right Cessation
- 2008-10-09 HR HRP20140214AT patent/HRP20140214T1/hr unknown
- 2008-10-09 BR BRPI0818617-0A patent/BRPI0818617A2/pt not_active Application Discontinuation
- 2008-10-09 PT PT88079371T patent/PT2207550E/pt unknown
- 2008-10-09 UA UAA201005122A patent/UA99150C2/ru unknown
- 2008-10-09 TW TW097139093A patent/TWI428129B/zh not_active IP Right Cessation
- 2008-10-09 CA CA2699504A patent/CA2699504C/en active Active
- 2008-10-09 AR ARP080104422A patent/AR068768A1/es unknown
- 2008-10-09 MY MYPI2010001561A patent/MY153044A/en unknown
- 2008-10-09 MX MX2010003711A patent/MX2010003711A/es active IP Right Grant
- 2008-10-09 PL PL08807937T patent/PL2207550T3/pl unknown
- 2008-10-09 NZ NZ585086A patent/NZ585086A/en not_active IP Right Cessation
-
2010
- 2010-04-06 IL IL204838A patent/IL204838A/en active IP Right Grant
- 2010-04-30 MA MA32806A patent/MA31800B1/fr unknown
- 2010-05-07 ZA ZA2010/03251A patent/ZA201003251B/en unknown
-
2014
- 2014-02-04 CY CY20141100085T patent/CY1114799T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009047723A3 (en) | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders | |
| MX2007004699A (es) | Derivados de indol y bencimidazol. | |
| GEP20125538B (en) | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases | |
| TW200833675A (en) | Nicotinamide derivatives | |
| WO2008019967A3 (en) | Phenyl, pyridine and quinoline derivatives | |
| MX2014015158A (es) | Derivados de piridinona y piridazinona. | |
| MX2010006241A (es) | Derivados de aminotriazol como agonistas de alx. | |
| WO2007135527A3 (en) | Benzimidazolyl compounds | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| MX2012004848A (es) | Compuestos heterociclicos triciclicos. | |
| PT2150530E (pt) | Derivados de sulfonamida substituídos | |
| MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
| MX2013000474A (es) | Derivados de arilamida novedosos que tienen propiedades antiandrogenicas. | |
| TN2009000287A1 (en) | Cyclized derivatives as eg-5inhibitors | |
| MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
| TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
| GEP20135806B (en) | Lactams as beta secretase inhibitors | |
| PL1753723T3 (pl) | Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych | |
| MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| TW200626158A (en) | Naphthaline derivatives | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| WO2009145591A3 (en) | Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |